STERISHEALTHCARE Products
Mumbai info@sterispharma.com
918824175417
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products GLIDAPAFLOZIN M 10/500
GLIDAPAFLOZIN M 10/5
GLIDAPAFLOZIN M 10/5
COD not available
DIABETIC RANGE by GLIDAPAFLOZIN M 10/500

GLIDAPAFLOZIN M 10/500

INR 192.5 INR 275
You Save: INR 82.5 (30%)
Check On
Share with
Check On
Share this on :

Description

Product details

GLIDAPAFLOZIN M 10/500 Dapagliflozin (10mg), Metformin (500mg) SR Introduction GLIDAPAFLOZIN M 10/500 combines two potent medications, Dapagliflozin (10 mg) and Metformin (500 mg, sustained-release), into a single tablet. This formulation offers a comprehensive approach to managing Type 2 diabetes by targeting both blood glucose levels and metabolic health. Mechanism of Action Dapagliflozin (10 mg): Dapagliflozin is an SGLT2 inhibitor that works in the kidneys to reduce glucose reabsorption, leading to increased urinary glucose excretion. This action helps lower blood glucose levels and can also promote weight loss and cardiovascular benefits. Metformin (500 mg, sustained-release): Metformin is a widely used medication that improves insulin sensitivity, reduces glucose production in the liver, and decreases intestinal glucose absorption. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects. Benefits GLIDAPAFLOZIN M 10/500 offers several benefits for individuals with Type 2 diabetes. By combining Dapagliflozin and Metformin, it provides dual-action control over blood glucose levels, enhances insulin sensitivity, and supports overall metabolic health. This combination can lead to improved glycemic control and may also assist in weight management. Dosage and Administration Dosage: The recommended dose is one tablet per day, taken with a meal. Dosage adjustments may be necessary based on individual response and tolerability. Administration: GLIDAPAFLOZIN M 10/500 should be taken in the morning to maximize its effectiveness throughout the day. It is important to follow the prescribed dosing schedule consistently. Side Effects Common side effects of GLIDAPAFLOZIN M 10/500 may include urinary tract infections, genital infections, and gastrointestinal disturbances such as nausea or diarrhea. These side effects are generally mild and transient, but patients should be aware of them and report any concerns to their healthcare provider. Conclusion GLIDAPAFLOZIN M 10/500 is a convenient and effective option for individuals with Type 2 diabetes, offering dual-action control over blood glucose levels and metabolic health. Its combination of Dapagliflozin and Metformin provides a comprehensive approach to diabetes management, potentially leading to improved outcomes and better quality of life. Patients should consult their healthcare provider for personalized advice on dosage and monitoring. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order Now https://www.sterisonline.com/product/glidapaflozin-m-10-500-133423

Keywords

Other Products

Related Products

GLIMITERIS MV1 0.2 is an advanced fixed-dose combination (FDC) medication designed for adults with Type 2 Diabetes Mellitus (T2DM) who require more than lifestyle modifications or single/dual therapy to maintain optimal blood sugar levels. This innovative formulation brings together the power of three well-established antidiabetic agents—Glimepiride (1 mg), Voglibose (0.2 mg), and Metformin Hydrochloride SR (500 mg)—to provide comprehensive glycemic control. It is particularly effective for patients struggling with postprandial hyperglycemia, fasting glucose regulation, and HbA1c reduction, making it a preferred choice in cases of poorly controlled diabetes. Mechanism of Action The therapeutic benefit of GLIMITERIS MV1 0.2 comes from the unique synergy of its three components, each targeting different aspects of glucose metabolism: 1. Glimepiride (1 mg) – Sulfonylurea Stimulates insulin secretion by activating pancreatic beta cells. Provides a long-lasting effect with comparatively lower hypoglycemia risk than older sulfonylureas. Helps reduce both fasting and postprandial glucose levels. 2. Voglibose (0.2 mg) – Alpha-Glucosidase Inhibitor Delays the breakdown and absorption of carbohydrates in the intestine. Minimizes post-meal glucose spikes (PPBG). Acts locally in the gut and has minimal systemic absorption, which reduces systemic side effects. 3. Metformin Hydrochloride SR (500 mg) – Biguanide Decreases hepatic glucose production (gluconeogenesis). Improves peripheral insulin sensitivity, enhancing glucose uptake in muscles. Does not cause hypoglycemia on its own. The sustained-release (SR) formulation ensures extended control and reduces gastrointestinal side effects. Indications GLIMITERIS MV1 0.2 is indicated for: Adults with Type 2 Diabetes Mellitus. Patients inadequately controlled with monotherapy or dual therapy. Management of fasting and postprandial hyperglycemia. Long-term HbA1c reduction as part of a comprehensive diabetes care plan. Key Benefits ✅ Comprehensive Blood Sugar Control – Acts on fasting, post-meal, and long-term HbA1c levels. ✅ Postprandial Spike Management – Voglibose effectively controls carbohydrate-induced sugar surges. ✅ Reduced Pill Burden – Combines three medicines into a single tablet. ✅ Lower Hypoglycemia Risk – Metformin and Voglibose balance out Glimepiride’s insulin-secreting effect. ✅ Weight Management Support – Metformin may promote modest weight loss or prevent weight gain. ✅ Improved Tolerability – SR formulation of Metformin enhances gastrointestinal comfort. Dosage and Administration Recommended dose: One tablet once or twice daily with meals, or as directed by the physician. Administration tips: Take with the first bite of a main meal to maximize Voglibose’s effect. Swallow whole with water; do not crush or chew the SR tablet. Dose adjustments: Based on blood sugar monitoring, clinical response, and renal/hepatic function. Contraindications GLIMITERIS MV1 0.2 is not suitable for patients with: Type 1 diabetes or diabetic ketoacidosis. Severe renal impairment (eGFR <30 mL/min/1.73 m²). Hepatic dysfunction. Severe gastrointestinal diseases. History of lactic acidosis. Hypersensitivity to Glimepiride, Voglibose, or Metformin. Pregnancy and lactation (unless strictly advised by a physician). Warnings and Precautions Hypoglycemia: Risk is higher when combined with other antidiabetics or with missed meals. Lactic Acidosis: A rare but life-threatening effect of Metformin—renal function monitoring is essential. GI Side Effects: Voglibose and Metformin may cause bloating, flatulence, or diarrhea (usually temporary). Vitamin B12 Monitoring: Long-term Metformin use may reduce B12 absorption. Liver and Kidney Function: Regular monitoring is recommended for safe long-term use. Adverse Effects Common: Glimepiride: Mild hypoglycemia, dizziness, slight weight gain. Voglibose: Gas, abdominal discomfort, mild diarrhea. Metformin SR: Nausea, bloating, metallic taste, loose stools. Rare but Serious: Lactic acidosis (from Metformin). Severe hypoglycemia (especially if meals are skipped). Allergic reactions such as rash, itching, or swelling. Elevated liver enzymes. Seek medical attention if symptoms such as rapid breathing, confusion, severe fatigue, or muscle pain occur. Drug Interactions Increased hypoglycemia risk: With insulin, beta-blockers, and sulfonylureas. Reduced Metformin efficacy: With corticosteroids, estrogens, and diuretics. Lactic acidosis risk: Higher with alcohol or iodinated contrast agents.
View Details
Glimepiride IP1 mg, Voglibose IP 0.2 MG & Metformin Hydrochloride IP 500 mg

INR263

BUDESHINE F 400 CAP - This is a combination inhalation therapy used in the management of asthma and Chronic Obstructive Pulmonary Disease (COPD). Mechanism of Action: Formoterol Fumarate: A long-acting β2-adrenergic agonist (LABA) that relaxes airway smooth muscles, providing rapid and sustained bronchodilation. Budesonide: An inhaled corticosteroid (ICS) that reduces airway inflammation, swelling, and mucus production. Together, they offer dual action—quick relief of bronchospasm and long-term control of airway inflammation. Indications: Asthma (for patients not controlled adequately with inhaled corticosteroids alone). Chronic Obstructive Pulmonary Disease (COPD) with reversible airway obstruction. Prevention of asthma attacks and reduction of COPD exacerbations. Key Benefits: Provides fast and sustained relief from breathing difficulty. Controls both inflammation and bronchospasm. Reduces the frequency and severity of asthma/COPD flare-ups. Improves overall lung function and quality of life. Dosage and Administration: Administered via inhalation as directed by a physician. Dose depends on the severity of disease and patient response. Regular use is required for effective control—not for acute asthma attacks. (Exact dosing schedule to be prescribed by the doctor.)
View Details
Formoterol Fumarate Dihydrate Ip 6 mcg & Budesonide IP 400 mcg

INR238

KEYPROFEN DT is a fast-acting nonsteroidal anti-inflammatory drug (NSAID) used to relieve moderate pain and inflammation. Its dispersible tablet form ensures quick dissolution and faster pain relief, making it convenient for oral administration. Ideal for managing post-operative pain, musculoskeletal discomfort, and other short-term pain conditions.
View Details
ketorolac tromethamine dispersible tablets 10 mg

INR166

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us